Patients Discontinuing Anti-Obesity Medications Regain Weight Four Times Faster Than Dieters

A recent study suggests that individuals who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass far faster than those who end traditional diet and exercise plans.

Published data in a leading health publication shows that while overweight individuals often shed substantial amounts of their total mass while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month after stopping.

"People using these treatments must be aware of the potential of fast weight regain when the treatment is stopped," cautioned expert Dr. Susan Jebb.

This pace of recovery means a reversion to original mass in about 18 months.

Comparing Therapies

The study, which examined dozens of studies involving thousands of participants, contrasted the results of these new drugs with older methods.

The team emphasize that people who shed pounds through dieting typically have a more gradual weight regain—perhaps 100 grams monthly—once they finish.

Explaining the Quick Rebound

Doctors propose the mechanism of the drugs is key to understanding the amplified regain.

GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which moderates appetite.

"Artificially providing GLP-1 concentrations several times higher than the body's typical production may cause the system to produce less of its endogenous hormone, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics researcher.

"Withdrawal of this hormone supplement results in appetite is unsuppressed, making overeating a significant risk."

An Ongoing Condition?

Medical guidelines advise the jabs for individuals with weight-linked medical conditions, alongside prescribed diet and exercise modifications.

A number of clinicians say that, given the significant potential of relapse, the treatment should be considered ongoing.

This view is reinforced by pharmaceutical companies, who say that the findings "underscore the chronic nature of excess weight," comparing it to managing diseases like diabetes.

Patient Experiences

People who have stopped the medication explain a intense resurgence of hunger.

"It felt as if a trigger flipping and I was suddenly extremely hungry," recalled one woman.

This difficulty is exacerbated if individuals have not established permanent lifestyle or habit modifications during treatment.

Widespread Interest

Survey data show that a significant number of adults in the UK have used these injections in the past year, with desire continuing to grow.

• Adoption is more common among females compared to males.
• The 40s and 50s demographic shows the greatest usage rates.
• A large proportion access the medications through private healthcare rather than the NHS.

Finally, experts stress that while GLP-1 drugs are potent tools for weight loss, they are not a standalone fix and maintained weight loss relies on integrated behavioural management.